Evidence map›Paper›PMID 40205274›Full record

ArticleDiscover oncology2025

A single-cell atlas of bladder cancer unveils dynamic cellular composition and endothelial functional shifts during progression.

Hongjian Song, Guixiang Xie, Yaowei Li, Xiaowei Hu, Zongzheng Yang, Yubo Zhao, Qing Shi, Haonan Li, Ziyi Liu, Zhihao Yin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. The role of HMGB1 in vascular endothelial cells.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hongjian Song *NHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Guixiang Xie *BGI Research, Chongqing, 401329, China.
Yaowei Li *NHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Xiaowei Hu *Department of Urogenital Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Zongzheng YangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Yubo ZhaoNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Qing ShiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Haonan LiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Ziyi LiuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Zhihao YinNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China.
Ziqi WangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China. wangziqi@hrbmu.edu.cn.
Zhichao TongNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China. zhichao.tong@hrbmu.edu.cn.
Wanhai XuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150001, China. xuwanhai@hrbmu.edu.cn.

Funding

China Postdoctoral Science Foundation 2021M693828Harbin Medical University Cancer Hospital Haiyan Foundation ZD2024-24Heilongjiang Provincial Department of Human Resources and Social Security LBH-Z22030Key Research and Development Program of Heilongjiang Province 2022ZX06C04Key Research and Development Program of Heilongjiang Province 2022ZX103C07National Key Research and Development Program of China 2021YFB3801000National Natural Science Foundation of China 82171999Nn10 project at Harbin Medical University Cancer Hospital Nn102024-01Spring Swallow Support Program for Young Talents from Heilongjiang Provincial Department of Science and Technology CYQN24038
6 · The paper itself

Abstract

purposeBladder cancer (BC) is characterized by high heterogeneity, with non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) stages differing significantly in clinical behavior and outcomes. The transition from NMIBC to MIBC involves extensive tumor microenvironment (TME) remodeling, particularly in endothelial cells (ECs), which drive angiogenesis and modulate immune and extracellular matrix (ECM) interactions. However, the precise roles of ECs in this progression remain poorly defined.

methodsPublic single-cell RNA sequencing (scRNA-seq) datasets from 47 BC patients were analyzed to characterize endothelial cell heterogeneity and functional states across NMIBC and MIBC. Computational tools such as CellChat were applied to reconstruct cell-cell communication networks, focusing on pathways related to angiogenesis, immune crosstalk, and ECM remodeling.

resultsTwelve major cell types were identified, with endothelial cells exhibiting distinct transcriptional profiles between NMIBC and MIBC. NMIBC-associated ECs promoted adhesion and migration through HMGB1 and CXCL12 signaling. In contrast, MIBC was enriched in an ADAM10

conclusionsThis study reveals stage-specific endothelial cell phenotypes and signaling networks in BC. The identification of an MIBC-specific ADAM10

Indexed as

Bladder cancerEndothelial cellSingle-cell RNA sequencingTumor microenvironment

Identifiers

PMID40205274
PMCPMC11982012

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.